Bristol-Myers Squibb's Taxol
Executive Summary
Three-hour infusion of drug at 135 mg/m or 175 mg/m for refractory ovarian cancer treatment is approved June 22. FDA's Oncology Drugs Advisory Committee recommended the three-hour infusion last fall ("The Pink Sheet" Sept. 27, 1993, T&G-8). Labeling had suggested a 24-hour infusion at 135 mg/m in refractory ovarian cancer. The three-hour schedule "provides physicians experienced in the use of cancer chemotherapeutic agents with an option to administer Taxol in outpatient settings where adequate diagnostic and treatment facilities are readily available," BMS says
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth